Pfizer Inc. $PFE is Barnett & Company Inc.’s 6th Largest Position

Barnett & Company Inc. reduced its position in Pfizer Inc. (NYSE:PFE) by 19.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 166,364 shares of the biopharmaceutical company’s stock after selling 39,523 shares during the period. Pfizer makes up about 3.3% of Barnett & Company Inc.’s investment portfolio, making the stock its 6th biggest position. Barnett & Company Inc.’s holdings in Pfizer were worth $4,142,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Sumitomo Mitsui Financial Group Inc. increased its position in Pfizer by 16.7% during the fourth quarter. Sumitomo Mitsui Financial Group Inc. now owns 190,203 shares of the biopharmaceutical company’s stock valued at $4,736,000 after acquiring an additional 27,199 shares during the last quarter. Xponance LLC lifted its holdings in Pfizer by 8.9% in the fourth quarter. Xponance LLC now owns 952,256 shares of the biopharmaceutical company’s stock valued at $23,711,000 after acquiring an additional 77,679 shares during the period. First Wilshire Securities Management Inc. purchased a new position in Pfizer in the fourth quarter worth about $201,000. Canopy Partners LLC grew its stake in shares of Pfizer by 6.7% during the 4th quarter. Canopy Partners LLC now owns 34,909 shares of the biopharmaceutical company’s stock valued at $869,000 after purchasing an additional 2,184 shares during the period. Finally, Keel Point LLC grew its stake in shares of Pfizer by 11.1% during the 4th quarter. Keel Point LLC now owns 20,289 shares of the biopharmaceutical company’s stock valued at $505,000 after purchasing an additional 2,034 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. HSBC raised their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Bank of America decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Pfizer in a research note on Monday, June 1st. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.82.

Pfizer Price Performance

Shares of Pfizer stock opened at $26.17 on Friday. The company has a market capitalization of $149.15 billion, a price-to-earnings ratio of 19.98 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The stock’s 50-day simple moving average is $26.48 and its 200-day simple moving average is $26.32. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter last year, the company earned $0.92 EPS. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s dividend payout ratio is currently 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded HYMPAVZI’s U.S. indication to include more hemophilia A and B patients, including pediatric use, improving Pfizer’s rare-disease growth outlook and potentially boosting future sales. Pfizer shares climb 3.2% as investors digest expanded U.S. label for HYMPAVZI
• Positive Sentiment: RBC Capital Markets upgraded Pfizer to Sector Perform, saying the stock’s recent weakness has improved the risk-reward profile and reset valuation ahead of key pipeline catalysts. Pfizer upgraded by RBC as valuation resets ahead of key pipeline catalysts
• Positive Sentiment: Multiple articles highlighted Pfizer’s obesity, oncology, and pneumococcal pipeline updates, signaling continued investment in new growth drivers beyond COVID-era revenues. Pfizer’s New Phase 1 PF-07799544 Study Adds Quiet Depth to Its R&D Pipeline
• Neutral Sentiment: Articles discussing Pfizer’s dividend yield and whether the stock is a buy or hold are mostly commentary, but they reinforce investor interest in PFE as an income name. A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25
• Negative Sentiment: Pfizer’s CEO warned that planned investment in Germany could be reconsidered because of proposed drug-pricing changes, underscoring ongoing policy risk for the company. Pfizer CEO warns German investment at risk over drug pricing policies

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.